|
Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). |
|
|
Consulting or Advisory Role - Abbvie; Celgene; Emergent BioSolutions; Genentech/Roche; Genzyme; Gilead Sciences; GlaxoSmithKline/Novartis; Merck; Pharmacyclics; Sanofi |
Research Funding - Abbvie; Acerta Pharma; Emergent BioSolutions; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Pharmacyclics |
|
|
Consulting or Advisory Role - Juno Therapeutics |
Speakers' Bureau - Pharmacyclics/Janssen; Seagen |
Research Funding - Acerta Pharma (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); TG Therapeutics (Inst) |
Travel, Accommodations, Expenses - Juno Therapeutics; Kite, a Gilead company |
|
|
Stock and Other Ownership Interests - RainTree Oncology Services |
Research Funding - Acerta Pharma (Inst); Agios (Inst); Calithera Biosciences (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunogen (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); TG Therapeutics (Inst); Trillium Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Genentech; Gilead Sciences; Pharmacyclics |
Research Funding - Abbvie; Genentech; Oncternal Therapeutics; Pharmacyclics |
|
|
Consulting or Advisory Role - Abbvie; Astellas Pharma; Genentech; Pharmacyclics; Verastem |
Speakers' Bureau - Abbvie; Genentech; Pharmacyclics |
|
|
Honoraria - Abbvie; Gilead Sciences; Janssen; Roche |
Consulting or Advisory Role - Abbvie; Janssen |
|
|
Consulting or Advisory Role - Gilead Sciences; Pharmacyclics |
|
|
Honoraria - Gilead Sciences; Janssen; Roche |
Consulting or Advisory Role - Abbvie; Gilead Sciences; Janssen; Merck; Mundipharma; Roche; Takeda |
Speakers' Bureau - Gilead Sciences; Johnson & Johnson; Roche |
|
|
Consulting or Advisory Role - Janssen; Roche |
Speakers' Bureau - Gilead Sciences; Janssen; Roche |
|
|
Consulting or Advisory Role - AbbVie; Adaptive Biotechnologies; Gilead Sciences; Janssen; Pharmacyclics; Roche |
Speakers' Bureau - Gilead Sciences |
Research Funding - AbbVie; Gilead Sciences; Janssen; Novartis |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
Patents, Royalties, Other Intellectual Property - Pharmacyclics |
Travel, Accommodations, Expenses - Pharmacyclics |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie; Amgen; Celgene |
|
|
Employment - CTI; Pharmacyclics |
Stock and Other Ownership Interests - Abbvie; CTI |
|
|
Employment - Abbvie/Pharmacyclics; Abbvie/Pharmacyclics (I) |
Stock and Other Ownership Interests - Abbvie; Abbvie (I) |
Patents, Royalties, Other Intellectual Property - Abbvie |
|
|
|
Consulting or Advisory Role - Janssen |
Research Funding - Janssen |